Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 13/2011

01-12-2011 | Bone and Soft Tissue Sarcomas

Sarcoma Lung Metastases Treated with Percutaneous Radiofrequency Ablation: Results from 29 Patients

Authors: J. Palussière, MD, A. Italiano, MD, E. Descat, MD, S. Ferron, MD, F. Cornélis, MD, A. Avril, MD, V. Brouste, MD, B. N. Bui, MD

Published in: Annals of Surgical Oncology | Issue 13/2011

Login to get access

Abstract

Purpose

We aimed to determine safety and efficacy of radiofrequency ablation (RFA) in the treatment of lung metastases arising from sarcoma.

Methods

Between 2002 and 2009, 29 patients (mean age 51 years) treated for metastatic sarcoma with a maximum of 5 lung metastases treatable with RFA were followed prospectively. The end points were local efficacy (assessed by computed tomography during the follow-up period), complications, and survival (overall and disease-free).

Results

A total of 47 metastases were treated with RFA. Median follow-up time was 50 months (range 28–72 months). Pneumothorax was the most frequent complication and occurred in 68.7% of the procedures. The 1- and 3-year survival rates were 92.2% (95% confidence interval [CI] 0.73–0.98) and 65.2% (95% CI 0.42–0.81), respectively. Disease-free survival was 7 months (95% CI 3.5–10). Five recurrences on RFA sites were noted during follow-up.

Conclusions

RFA is safe and efficient in the treatment of lung metastasis originating from sarcomas. RFA may provide a low-morbidity alternative to surgery, being less invasive and preserving the patient’s ability to undergo possible repeat operations.
Literature
1.
Gadd MA, Casper ES, Woodruff JM, et al. Development and treatment of pulmonary metastases in adult patients with extremity soft tissue sarcoma. Ann Surg. 1993;218:705–12.PubMedCrossRef
2.
van Geel AN, Pastorino U, Jauch KW, et al. Surgical treatment of lung metastases: the European Organization for Research and Treatment of Cancer—Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer. 1996;77:675–82.PubMedCrossRef
3.
Pastorino U, Valente M, Gasparini M, et al. Lung resection for metastatic sarcomas: total survival from primary treatment. J Surg Oncol. 1989;40:275–80.PubMedCrossRef
4.
Weiser MR, Downey RJ, Leung DH, Brennan MF. Repeat resection of pulmonary metastases in patients with soft-tissue sarcoma. J Am Coll Surg. 2000;191:184–90.PubMedCrossRef
5.
Liebl LS, Elson F, Quaas A, et al. Value of repeat resection for survival in pulmonary metastases from soft tissue sarcoma. Anticancer Res. 2007;27:2897–902.PubMed
6.
Rehders A, Hosch SB, Scheunemann P, et al. Benefit of surgical treatment of lung metastasis in soft tissue sarcoma. Arch Surg. 2007;142:70–5.PubMedCrossRef
7.
Seynaeve C, Verweij J. High-dose chemotherapy in adult sarcomas: no standard yet. Semin Oncol. 1999;26:119–33.PubMed
8.
Ueda T, Uchida A, Kodama K, et al. Aggressive pulmonary metastasectomy for soft tissue sarcomas. Cancer. 1993;72:1919–25.PubMedCrossRef
9.
Abbas G, Schuchert MJ, Pennathur A, et al. Ablative treatments for lung tumors: radiofrequency ablation, stereotactic radiosurgery, and microwave ablation. Thorac Surg Clin. 2007;17:261–71.PubMedCrossRef
10.
Dupuy DE, Mayo-Smith WW, Abbott GF, DiPetrillo T. Clinical applications of radio-frequency tumor ablation in the thorax. Radiographics. 2002;22(Spec. No.):S259–69.PubMed
11.
Rose SC, Thistlethwaite PA, Sewell PE, Vance RB. Lung cancer and radiofrequency ablation. J Vasc Interv Radiol. 2006;17:927–51.PubMedCrossRef
12.
Suh R, Reckamp K, Zeidler M, Cameron R. Radiofrequency ablation in lung cancer: promising results in safety and efficacy. Oncology (Williston Park). 2005;19 (11 Suppl. 4):12–21.
13.
Simon CJ, Dupuy DE, DiPetrillo TA, et al. Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients. Radiology. 2007;243:268–75.PubMedCrossRef
14.
Yan TD, King J, Sjarif A, et al. Percutaneous radiofrequency ablation of pulmonary metastases from colorectal carcinoma: prognostic determinants for survival. Ann Surg Oncol. 2006;13:1529–37.PubMedCrossRef
15.
Yan TD, King J, Sjarif A, et al. Treatment failure after percutaneous radiofrequency ablation for nonsurgical candidates with pulmonary metastases from colorectal carcinoma. Ann Surg Oncol. 2007;14:1718–26.PubMedCrossRef
16.
de Baère T, Palussière J, Auperin A, et al. Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology. 2006;240:587–96.PubMedCrossRef
17.
Weiser MR, Downey RJ, Leung DH, et al. Repeat resection of pulmonary metastases in patients with soft-tissue sarcoma. J Am Coll Surg. 2000;191:184–90.PubMedCrossRef
18.
Anderson EM, Lees WR, Gillams AR. Early indicators of treatment success after percutaneous radiofrequency of pulmonary tumors. Cardiovasc Intervent Radiol. 2009;32:478–83.PubMedCrossRef
19.
Shuster JJ. Median follow-up in clinical trials. J Clin Oncol. 1991;9:191–92.PubMed
20.
Cannella M, Cornelis F, Descat E, et al. Bronchopleural fistula after radiofrequency ablation of lung tumours. Cardiovasc Intervent Radiol. 2010;34(Suppl. 2):S171–4.PubMed
21.
Billingsley KG, Burt ME, Jara E, et al. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann Surg. 1999;229:602–10.PubMedCrossRef
22.
Smith R, Pak Y, Kraybill W, Kane JM 3rd. Factors associated with actual long-term survival following soft tissue sarcoma pulmonary metastasectomy. Eur J Surg Oncol. 2009;35:356–61.PubMedCrossRef
23.
Gossot D, Radu C, Girard P, et al. Resection of pulmonary metastases from sarcoma: can some patients benefit from a less invasive approach? Ann Thorac Surg. 2009;87:238–43.PubMedCrossRef
24.
Nakamura T, Matsumine A, Yamakado K, et al. Lung radiofrequency ablation in patients with pulmonary metastases from musculoskeletal sarcomas Cancer. 2009;115:3774–81.PubMedCrossRef
25.
Ahmed M, Liu Z, Afzal KS, et al. Radiofrequency ablation: effect of surrounding tissue composition on coagulation necrosis in a canine tumor model. Radiology. 2004;230:761–7.PubMedCrossRef
26.
de Baère T. Lung tumor radiofrequency ablation: where do we stand? Cardiovasc Intervent Radiol. 2011;34:241–51.PubMedCrossRef
27.
Gillams AR, Lees WR. Radiofrequency ablation of lung metastases: factors influencing success. Eur Radiol. 2008;18:672–7.PubMedCrossRef
28.
Iguchi T, Hiraki T, Gobara H, et al. Percutaneous radiofrequency ablation of lung tumors close to the heart or aorta: evaluation of safety and effectiveness. J Vasc Interv Radiol. 2007;18:733–40.PubMedCrossRef
29.
Hiraki T, Sakurai J, Tsuda T, et al. Risk factors for local progression after percutaneous radiofrequency ablation of lung tumors: evaluation based on a preliminary review of 342 tumors. Cancer. 2006;107:2873–80.PubMedCrossRef
30.
Beland MD, Wasser EJ, Mayo-Smith WW, Dupuy DE. Primary non-small cell lung cancer: review of frequency, location, and time of recurrence after radiofrequency ablation. Radiology. 2010;254:301–7.PubMed
31.
Hataji O, Yamakado K, Nakatsuka A, et al. Radiological and pathological correlation of lung malignant tumors treated with percutaneous radiofrequency ablation. Intern Med. 2005;44:865–9.PubMedCrossRef
32.
Hiraki T, Gobara H, Mimura H, et al. Does tumor type affect local control by radiofrequency ablation in the lungs? Eur J Radiol. 2010;74:136–41.PubMedCrossRef
33.
Blackmon SH, Shah N, Roth JA, et al. Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long term survival. Ann Thorac Surg. 2009;88:877–84.PubMedCrossRef
34.
Pouliquen C, Kabbani Y, Saignac P, et al. Radiofrequency ablation of lung tumors under thoracic epidural anaesthesia. A case report. Cardiovasc Intervent Radiol. In press.
35.
Sano Y, Kanazawa S, Mimura H, et al. A novel strategy for treatment of metastatic pulmonary tumors: radiofrequency ablation in conjunction with surgery. J Thorac Oncol. 2008;3:283–8.PubMedCrossRef
36.
Margaritora S, Porziella V, D’Andrilli A, et al. Pulmonary metastases: can accurate radiological evaluation avoid thoracotomic approach? Eur J Cardiothorac Surg. 2002;21:1111–4.PubMedCrossRef
37.
Parsons AM, Detterbeck FC, Parker LA. Accuracy of helical CT in the detection of pulmonary metastases: is intraoperative palpation still necessary? Ann Thorac Surg. 2004;78:1910–6.PubMedCrossRef
38.
Nakajima J, Murakawa T, Fukami T, et al. Is finger palpation at surgery indispensable for pulmonary metastasectomy in colorectal cancer? Ann Thorac Surg. 2007;84:1680–4.PubMedCrossRef
39.
Italiano A, Mathoulin-Pelissier S, Cesne AL, et al. Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer. 2011;117:1049–54.PubMedCrossRef
Metadata
Title
Sarcoma Lung Metastases Treated with Percutaneous Radiofrequency Ablation: Results from 29 Patients
Authors
J. Palussière, MD
A. Italiano, MD
E. Descat, MD
S. Ferron, MD
F. Cornélis, MD
A. Avril, MD
V. Brouste, MD
B. N. Bui, MD
Publication date
01-12-2011
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 13/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-011-1806-0

Other articles of this Issue 13/2011

Annals of Surgical Oncology 13/2011 Go to the issue

Colorectal Cancer

Recurrence Rates and Prognostic Factors in ypN0 Rectal Cancer After Neoadjuvant Chemoradiation and Total Mesorectal Excision

Gynecologic Oncology

Prognostic Value of Pathological Resection Margin Distance in Squamous Cell Cancer of the Vulva

Pancreatic Tumors

Survival and Quality of Life of Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Interferon-Based Chemoradiation: A Phase II Trial

Breast Oncology

Sentinel Lymph Node Pressure in Breast Cancer

Colorectal Cancer

Survival and Quality of Life Following Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colonic Origin

Gastrointestinal Oncology

Viable Tumor Tissue Adherent to Needle Applicators after Local Ablation: A Risk Factor for Local Tumor Progression